BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23416951)

  • 1. Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak.
    Feldt-Rasmussen U; Brabant G; Maiter D; Jonsson B; Toogood A; Koltowska-Haggstrom M; Rasmussen AK; Buchfelder M; Saller B; Biller BM
    Eur J Endocrinol; 2013 May; 168(5):733-43. PubMed ID: 23416951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board.
    Bengtsson BA; Abs R; Bennmarker H; Monson JP; Feldt-Rasmussen U; Hernberg-Stahl E; Westberg B; Wilton P; Wüster C
    J Clin Endocrinol Metab; 1999 Nov; 84(11):3929-35. PubMed ID: 10566630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis.
    Abs R; Feldt-Rasmussen U; Mattsson AF; Monson JP; Bengtsson BA; Góth MI; Wilton P; Koltowska-Häggström M
    Eur J Endocrinol; 2006 Jul; 155(1):79-90. PubMed ID: 16793953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults.
    Feldt-Rasmussen U; Wilton P; Jonsson P; ;
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S51-8. PubMed ID: 15135778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database.
    Kelestimur F; Jonsson P; Molvalilar S; Gomez JM; Auernhammer CJ; Colak R; Koltowska-Häggström M; Goth MI
    Eur J Endocrinol; 2005 Apr; 152(4):581-7. PubMed ID: 15817914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database.
    Abs R; Mattsson AF; Bengtsson BA; Feldt-Rasmussen U; Góth MI; Koltowska-Häggström M; Monson JP; Verhelst J; Wilton P;
    Growth Horm IGF Res; 2005 Oct; 15(5):349-59. PubMed ID: 16168692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of residual growth hormone (GH) response to provocative testing in adults with severe GH deficiency.
    Brabant G; Krogh Rasmussen A; Biller BM; Buchfelder M; Feldt-Rasmussen U; Forssmann K; Jonsson B; Koltowska-Haggstrom M; Maiter D; Saller B; Toogood A
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2604-9. PubMed ID: 17488801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proposal of a clinical response score and predictors of clinical response to 2 years of GH replacement therapy in adult GH deficiency.
    Schneider HJ; Buchfelder M; Wallaschofski H; Luger A; Johannsson G; Kann PH; Mattsson A
    Eur J Endocrinol; 2015 Dec; 173(6):843-51. PubMed ID: 26369579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the Study of Health in Pomerania.
    Moock J; Albrecht C; Friedrich N; Völzke H; Nauck M; Koltowska-Haggström M; Kohlmann T; Wallaschofski H
    Eur J Endocrinol; 2009 Jan; 160(1):17-24. PubMed ID: 18974232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome.
    Tanriverdi F; Unluhizarci K; Kula M; Guven M; Bayram F; Kelestimur F
    Growth Horm IGF Res; 2005 Jun; 15(3):231-7. PubMed ID: 15921942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database).
    Verhelst J; Kendall-Taylor P; Erfurth EM; Price DA; Geffner M; Koltowska-Häggström M; Jönsson PJ; Wilton P; Abs R
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4636-43. PubMed ID: 15928246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone deficiency and replacement in elderly hypopituitary adults. KIMS Study Group and the KIMS International Board. Pharmacia and Upjohn International Metabolic Database.
    Monson JP; Abs R; Bengtsson BA; Bennmarker H; Feldt-Rasmussen U; Hernberg-Stâhl E; Thorén M; Westberg B; Wilton P; Wüster C
    Clin Endocrinol (Oxf); 2000 Sep; 53(3):281-9. PubMed ID: 10971444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influences on quality of life in GH deficient adults and their effect on response to treatment.
    Murray RD; Skillicorn CJ; Howell SJ; Lissett CA; Rahim A; Smethurst LE; Shalet SM
    Clin Endocrinol (Oxf); 1999 Nov; 51(5):565-73. PubMed ID: 10594517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to growth hormone treatment in isolated growth hormone deficiency versus multiple pituitary hormone deficiency.
    Darendeliler F; Lindberg A; Wilton P
    Horm Res Paediatr; 2011; 76 Suppl 1():42-6. PubMed ID: 21778748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy.
    Monson JP; Jönsson P; Koltowska-Häggström M; Kourides I
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):623-8. PubMed ID: 17581260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GH replacement in hypopituitarism improves lipid profile and quality of life independently of changes in obesity variables.
    Abrams P; Boquete H; Fideleff H; Feldt-Rasmussen U; Jönsson PJ; Koltowska-Häggström M; Wilton P; Abs R
    Eur J Endocrinol; 2008 Dec; 159(6):825-32. PubMed ID: 18713841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database).
    Popovic V; Mattsson AF; Gaillard RC; Wilton P; Koltowska-Häggström M; Ranke MB
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4449-54. PubMed ID: 20610598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response.
    Svensson J; Finer N; Bouloux P; Bevan J; Jonsson B; Mattsson AF; Lundberg M; Harris PE; Koltowska-Häggström M; Monson JP;
    Growth Horm IGF Res; 2007 Feb; 17(1):67-76. PubMed ID: 17223598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency.
    Colao A; Cerbone G; Pivonello R; Aimaretti G; Loche S; Di Somma C; Faggiano A; Corneli G; Ghigo E; Lombardi G
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1277-82. PubMed ID: 10199767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of long-term GH replacement therapy on cardiovascular outcomes in isolated GH deficiency compared with multiple pituitary hormone deficiencies: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults.
    van Bunderen CC; van den Dries CJ; Heymans MW; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
    Eur J Endocrinol; 2014 Aug; 171(2):151-60. PubMed ID: 24801587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.